CD274 and non-small cell lung carcinoma: To date, three therapeutic antibodies targeting the PD-1/PD-L1 signal pathway have been approved by the FDA in the use of metastatic melanoma, NSCLC, renal cell cancer or urothelial carcinoma, with several others in clinical trials in preparation for release to the open market (Table 15) [84].